Intestinal cytochromes P450 regulating the intestinal microbiota and its probiotic profile

References

• Gonzalez FJ, Nebert DW. Evolution of the P450 gene superfamily: animal-plant ‘warfare’, molecular drive and human genetic differences in drug oxidation. Trends Gen. 1990; 6: 182–6. 10.3402/mehd.v23i0.18370.
   PubMed Web of Science ®Google Scholar
• Nebert DW. Polymorphisms in drug metabolizing enzymes: what is their clinical relevance and why do they exist?. Am J Hum Genet. 1997; 60: 265–71.
   PubMed Web of Science ®Google Scholar
• Omiecinski CJ, Remmel RP, Hosagrahara VP. Concise review of the cytochrome P450s and their roles in toxicology. Toxicol Sci. 1999; 48: 151–6. 10.3402/mehd.v23i0.18370.
   PubMed Web of Science ®Google Scholar
• Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. The human intestinal cytochrome P450 ‘pie’. Drug Metabolism Dispos. 2006; 34: 880–6. 10.3402/mehd.v23i0.18370.
   PubMed Web of Science ®Google Scholar
• Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, et al. P450 superfamily: update on new sequences, gene mapping, accession numbers, and nomenclature. Pharmacogenetics. 1996; 6: 1–42. 10.3402/mehd.v23i0.18370.
   PubMedGoogle Scholar
• Lewis DFV, Hlavica P. Interactions between redox partners in various cytochrome P450 systems: functional and structural aspects. Biochim Biophys Acta. 2000; 1460: 353–74. 10.3402/mehd.v23i0.18370.
   PubMed Web of Science ®Google Scholar
• Sligar SG, Makris TM, Denisov IG. Thirty years of microbial P450 monooxygenase research: peroxo-heme intermediates—the central bus station in heme oxygenase catalysis. Biochem Biophys Res Commun. 2005; 338: 346–54. 10.3402/mehd.v23i0.18370.
   PubMedGoogle Scholar
• Engman HA, Lennernas H, Taipalensuu J, Otter C, Leidvik B, Artuson P. CYP3A4, CYP3A5, and MDR1 in human small and large intestinal cell lines suitable for drug transport studies. J Pharm Sci. 2001; 90: 1736–51. 10.3402/mehd.v23i0.18370.
   PubMed Web of Science ®Google Scholar
• Chang GWM, Kam PCA. The physiological and pharmacological roles of cytochrome P450 isoenzymes. Anaesthesia. 1999; 54: 42–50. 10.3402/mehd.v23i0.18370.
   PubMed Web of Science ®Google Scholar
• Spatzenegger M, Horsmans Y, Verbeeck RC. Differential activities of CYP1A isozymes in hepatic and intestinal microsomes of control and 3-methylcholanthrene induced rats. Pharmacol Toxicol. 2000; 86: 71–7. 10.3402/mehd.v23i0.18370.
   PubMedGoogle Scholar
• Tredger JM, Stoll S. Cytochromes P450 – their impact on drug treatment. Hospital Pharmacist. 2002; 9: 167–73.
   Google Scholar
• Johnson TN, Tanner MS, Taylor CJ, Tucker GT. Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of celiac disease and cystic fibrosis. Brit J Clin Pharmacol. 2001; 51: 451–60. 10.3402/mehd.v23i0.18370.
   PubMed Web of Science ®Google Scholar
• Ding X, Kaminsky LS. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue selective chemical toxicity in the respiratory and gastrointestinal tracts. Ann Rev Pharmacol Toxicol. 2002; 43: 149–73.
   PubMed Web of Science ®Google Scholar
• Galland L. Leaky gut syndromes: breaking the vicious cycle. Foundation Integrated Medicine, Renaissance Workshops Ltd., , 2007. Available from: http://curezone.com/forums/fm.asp?i=1696028 [cited 25 September 2010]..
   Google Scholar
• Benedetti MS, Baltes EL. Drug metabolism and disposition in children Fund. Clin Pharmacol. 2003; 17: 281–99.
   Google Scholar
• Werck-Reichhart D, Feyereisen R. Cytochromes P450: a success story. Genome Biol. 2000: 1(6): 3003.1–3003.9. 10.3402/mehd.v23i0.18370.
   Google Scholar
• Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF. Sex differences in pharmacokinetics and pharmacodynamics. Ann Rev Pharmacol Toxicol. 2004; 44: 499–23. 10.3402/mehd.v23i0.18370.
   PubMed Web of Science ®Google Scholar
• Gonzalez FJ. The role of peroxisome proliferators activated receptor alpha in peroxisome proliferation, physiological homeostasis, and chemical carcinogenesis. Adv Exp Med Biol. 1997; 422: 109–25.
   PubMed Web of Science ®Google Scholar
• Palasz A, Wiaderkiewicz A, Wiaderkiewicz R, Czekaj P, Czajkowska B, Lebda-Wyborny T, et al. Age-related changes in the mRNA levels of CYP1A1, CYP2B1/2 and CYP3A1 isoforms in rat small intestine. Genes Nutr. 2012; 7: 197–207. 10.3402/mehd.v23i0.18370.
   PubMed Web of Science ®Google Scholar
• Fisher MB, Labissiere G. The role of the intestine in drug metabolism and pharmacokinetics: an industry perspective. Current Drug Metabol. 2007; 8: 694–9. 10.3402/mehd.v23i0.18370.
   PubMed Web of Science ®Google Scholar
• Lundin A, Chek Mei B, Aronsson L, Bjorkholm B, Gustafsson JA, Pott S, et al. Gut flora, toll-like receptors: a tripartite communication that tunes innate immunity in large intestine. Cell Microbiol. 2008; 10: 1093–103. 10.3402/mehd.v23i0.18370.
   Google Scholar
• Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet. 2002; 360: 1155–62. 10.3402/mehd.v23i0.18370.
   PubMed Web of Science ®Google Scholar
• Wildt de SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinetics. 1999; 37: 485–505. 10.3402/mehd.v23i0.18370.
   Google Scholar
• Okita RT. The cytochrome P450 system: helping to teach its importance in drug metabolism and drug interactions. Am J Pharm Educ. 1996; 60: 205–7.
   Web of Science ®Google Scholar
• Sandson NB, Arlington MD. Drug interactions casebook: the cytochrome P450 system and beyond. Am J Psych. 2003; 161: 2145–6.
   Google Scholar
• Pinto AG, Horlander J, Chalasani N, Hamman M, Asghar A, Kolwankar D, et al. Diltiazem inhibits human intestinal cytochrome P450 3A (CYP3A) activity in vivo without altering the expression of intestinal mRNA protein. Brit J Clin Pharmacol. 2005; 59: 440–6. 10.3402/mehd.v23i0.18370.
   PubMed Web of Science ®Google Scholar
• Gonzalez FJ, Gelboin HV. Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metabol Rev. 1994; 26: 165–83. 10.3402/mehd.v23i0.18370.
   PubMed Web of Science ®Google Scholar
• Crofts FG, Strickland PT, Hayes CL, Sutter TR. Metabolism of a 2 amino 1 methyl 6 phenylimidazo[4,5 b]pyridine (PhIP) by human cytochrome P4501B1. Carcinogenesis. 1997; 18: 1793–8. 10.3402/mehd.v23i0.18370.
   PubMed Web of Science ®Google Scholar
• Gonzalez FJ, Liu SY, Yano M. Regulation of cytochrome P450 genes: molecular mechanisms. Pharmacogenetics. 1993; 3: 51–7. 10.3402/mehd.v23i0.18370.
   PubMedGoogle Scholar
• Parkinson A. Biotransformation of xenobiotics. Casarett & Doull's toxicology: the basic science of poisons5th ed. Klaassen CD. McGraw-Hill: New York, 1996; 113–86.
   Google Scholar
• Rahman A, Korzekwa KR, Grogan J, Gonzales FJ, Harris JW. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res. 2004; 54: 5543–6.
   Google Scholar
• McTernan PG, Anwar A, Eggo M, Barnett AH, Stewart PM, Kumar S. Gender differences in the regulation of P450 aromatase expression and activity in human adipose tissue. Int J Obes. 2002; 24: 875–81. 10.3402/mehd.v23i0.18370.
   Google Scholar
• Daly AK, Brockmoller J, Broly F, Eichelbaum M, Evans WE, Gonzales FJ, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics. 1996; 6: 193–201. 10.3402/mehd.v23i0.18370.
   PubMedGoogle Scholar
• Kaminsky LS, Spivack SD. Cytochromes P450 and cancer. Mol Aspects Med. 1999; 20: 70–84.
   PubMedGoogle Scholar
• Catterall F, McArdle NJ, Mitchell L, Papayanni A, Clifford MN, Ioannides C. Hepatic and intestinal cytochrome P450 and conjugase activities in rats treated with black tea theafulvins and theaflavins. Food Chem Toxicol. 2003; 41: 1141–7. 10.3402/mehd.v23i0.18370.
   PubMedGoogle Scholar
• Rendic S, Di-Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metabol Rev. 1999; 29: 413–580. 10.3402/mehd.v23i0.18370.
   Google Scholar
• Wilkinson GR. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm. 1996; 24: 475–90.
   PubMedGoogle Scholar
• Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Ann Rev Pharmacol Toxicol. 1998; 38: 389–430. 10.3402/mehd.v23i0.18370.
   PubMed Web of Science ®Google Scholar
• Simpson AE. The cytochrome P450 4 (CYP4) family. Gen Pharmacol. 1997; 28: 351–9. 10.3402/mehd.v23i0.18370.
   PubMedGoogle Scholar
• Prior T, Baker G. Interactions between the cytochrome P450 system and the second –generation antophychotics. J Phychiatr Neurosci. 2002; 28: 99–112.
   Web of Science ®Google Scholar
• McLellan F. US government released on deceptive drug advertisements. Lancet. 2002; 360: 1951–4. 10.3402/mehd.v23i0.18370.
   Google Scholar
• Krishna DR, Klotz U. Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet. 1994; 26: 144–60. 10.3402/mehd.v23i0.18370.
   PubMed Web of Science ®Google Scholar
• Midtvedt T. Microbial P450: does it exist, and what can it mean?. In: Heidt JP, Midtvedt T, Rusch V, Der Waalj Van D Old Herborn University, Monograph 16 Complete Volume. Old Herborn University Seminar No. 16, 2003: 51–56.
   Google Scholar
• Bezirtzoglou E, Norin E, Midvedt T. Influence of roxithromycin on some microflora associated characteristics. Microecol Ther. 1999; 28: 241–7.
   Google Scholar
• Nugan-Baudon L, Rabot S, Flinois JP, Lory S, Beaune P. Effects of the bacterial status of rats on the changes in some liver cytochromes P450 (EC 1.14.14.1) apoproteins consequent to a glucosinolate-rich diet. Brit J Nutr. 1998; 80: 231–4.
   Web of Science ®Google Scholar
• John G, Walls S, Keith R, Goodfox-Jones J, Tucker K, Abraham KJ. The presence of cytochrome P450-like protein in the human intestinal microflora Eubacterium aerofaciens. Microb Ecol Health Dis. 2001; 13: 3–8. 10.3402/mehd.v23i0.18370.
   Google Scholar
• Sperry JF, Wilkins TD. Presence of cytochrome c in Desulfomonas pigra. J Bacteriol. 1997; 129: 554–5.
   Google Scholar
• Lamb DC, Skaug T, Hong-Lin Song Jachson CJ, Podust LM, Waterman MR, Kell DB, et al. The cytochrome P450 complement (CYPome) of Streptomyces coelicolor A3(2). J Biol Chem. 2002; 277: 2400–5.
   Web of Science ®Google Scholar
• Lei L, Waterman MR, Fulco AJ, Kelly SL. Availability of specific reductases controls the temporal a cytochrome P450 complement of Streptomyces coelicolor. Proc Natl Acad Sci. 2004; 101: 494–9. 10.3402/mehd.v23i0.18370.
   Google Scholar
• Mehta T, Coppi MV, Childers SE, Lovley DR. Outer membrane c-type cytochromes required for Fe(III) oxide reduction in Geobacter sulfurreducens. Appl Environ Microbiol. 2005; 71: 8634–41. 10.3402/mehd.v23i0.18370.
   PubMed Web of Science ®Google Scholar
• Sperry JF, Wilkins TD. Cytochrome spectrum of an obligate anaerobe Eubacterium lentum. J Bacteriol. 1976; 125: 905–9.
   Web of Science ®Google Scholar
• Leblond FA, Petrucci M, Dube P, Bernier G, Bonnardeaux A, Pichette V. Downregulation of intestinal cytochrome P450 in chronic renal failure. J Am Soc Nephrol. 2002; 13: 1579–85. 10.3402/mehd.v23i0.18370.
   PubMed Web of Science ®Google Scholar
• Nils-Georg A, Mollby R, Noris L, Wadstrom T. Probiotics in gastric and intestinal disorders as functional food and medicine. Scand J Nutr. 2004; 48: 15–25. 10.3402/mehd.v23i0.18370.
   Google Scholar
• Midtvedt T, Bjørneklett A, Carlstedt-Duke B, Gustafsson BE, Høverstad T, Lingaas E, et al. The influence of antibiotics upon microflora-associated characteristics in man and mammals. Prog Clin Biol Res. 1985; 181: 241–4.
   Google Scholar
• Bezirtzoglou E, Stavropoulou E. Immunology and probiotic impact of the newborn and young children intestinal microflora. Anaerobe. 2011; 17: 369–74. 10.3402/mehd.v23i0.18370.
   PubMed Web of Science ®Google Scholar
• Vassos D, Maipa V, Voidarou C, Alexopoulos A, Bezirtzoglou E. Development of human lactic acid (LAB) gastrointestinal microbiota in Greek rural population. Centre Eur J Biol. 2008; 3: 55–60. 10.3402/mehd.v23i0.18370.
   Google Scholar
• Lieber CS. Microsomal ethanol-oxidizing system (MEOS) – a review. Alcoholism: Clin Exp Res. 1999; 23: 991–1007.
   PubMed Web of Science ®Google Scholar
• Bradford BU, Kono H, Isayama F, Kosyk O, Wheeler MD, Akiyama TE, Bleye L, et al. Cytochrome P450 CYP2E1, but not nicotinamide adenine dinucleotide phosphate oxidase, is required for ethanol-induced oxidative DNA damage in rodent liver. Hepatology. 41; (2): 336–44. 10.3402/mehd.v23i0.18370.
   Google Scholar
• Gong P, Cederbaum AI. Nrf2 is increased by CYP2E1 in rodent liver and HepG2 cells and protects against oxidative stress caused by CYP2E1. Hepatology. 2006; 43: 144–53. 10.3402/mehd.v23i0.18370.
   PubMed Web of Science ®Google Scholar
• Gonzalez FJ. Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1. Mutat Res. 2005; 569: 101–10. 10.3402/mehd.v23i0.18370.
   PubMed Web of Science ®Google Scholar
• Cohen-Kerem R, Koren G. Antioxidants and fetal protection against ethanol teratogenicity. Neurotoxicol Teratol. 2003; 25: 1–9. 10.3402/mehd.v23i0.18370.
   PubMed Web of Science ®Google Scholar
• Cavalieri EL, Li KM, Balu N, Sahaaed M, Devanesan P, Higginbotham S, Zhao J, et al. Catechol ortho-quinones: the electrophilic compounds that form depurinating DNA adducts and could initiate cancer and other diseases. Carcinogenesis. 2002; 23: 1071–7. 10.3402/mehd.v23i0.18370.
   PubMed Web of Science ®Google Scholar
• Ball P, Knuppen R. Catecholoestrogens (2- and 4-hydroxyestrogens): chemistry, biogenesis, metabolism, occurrence and physiological significance. Acta Endocrinol Suppl (Copenh). 1980; 232: 1–127.
   PubMedGoogle Scholar
• Martucci CP, Fishman J. P450 enzymes of estrogen metabolism. Pharmacol Ther. 1993; 57: 237–57. 10.3402/mehd.v23i0.18370.
   PubMed Web of Science ®Google Scholar
• Mahabir S, Ettinger S, Johnson L, Baer DJ, Clevidence BA, Hartman TJ, Taylor PR. Measures of adiposity and body fat distribution in relation to serum folate levels in postmenopausal women in a feeding study. Eur J Clin Nutr. 2008; 62: 644–50. 10.3402/mehd.v23i0.18370.
   PubMed Web of Science ®Google Scholar
• Stack DE, Byun J, Gross ML, Rogan EG, Cavalieri EL. Molecular characteristics of catechol estrogen quinones in reactions with deoxyribonucleosides. Chem Res Toxicol. 1996; 9: 851–9. 10.3402/mehd.v23i0.18370.
   PubMed Web of Science ®Google Scholar
• Cavalieri EL, Stack DE, Devanesan PD, Todorovic R, Dwivedy I, Higginbotham S, et al. Molecular origin of cancer: catechol estrogen-3, 4-quinones as endogenous tumor initiators. Proc Natl Acad Sci USA. 1997; 94: 10937–42. 10.3402/mehd.v23i0.18370.
   PubMed Web of Science ®Google Scholar